|
KMID : 0391020030110010030
|
|
Journal of Korean Society for Clinical Pharmacology and Therapeutics
2003 Volume.11 No. 1 p.30 ~ p.37
|
|
|
Pharmacokinetics of Rosiglitazone in Korean Healthy Subjects
|
|
Kim Su-Young
Youn Un-Ki
Jung Myung-Sub
Kim Kyoung-Ah
|
|
|
Abstract
|
|
|
Background : Rosiglitazone is a novel thiazolinedione anti-diabetic drug and metabolized by cytochrome P450 2C8. A number of studies have evaluated the pharmacokinetic profiles of rosiglitazone in different ethnic groups but there is no available data for Korean subjects.
Methods : Nine healthy Korean male subjects were treated 8 mg rosiglitazone orally. Plasma rosiglitazone concentrations were measured using high performance liquid chromatography and pharmacokinetic analysis was done using non-compartmental method.
Results : Pharmacokinetic variables of rosiglitazone in Koreans healthy subjects are as follows: {C_{max},;535.6;{pm};123.9 ;ng/mL;} elimination half life, {3.9;{pm};0.3h;;AUC_{0-inf},;2886.2 ;{pm};471.8;ng{cdot}h/mL,} oral clearance, 2.8;{pm};0.5 L/h. The variation of pharmacokinetic variables was less than 20% except C_{max};and;T_{max}.
Conclusion: This study showed that Korean showed similar pharmacokinetic characteristics to Caucasians.
|
|
|
KEYWORD
|
|
|
Rosiglitazone, Pharmacokinetics, CYP2C8, Koreans, Ethnic Difference
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
 
|